obe001 and atosiban

obe001 has been researched along with atosiban* in 2 studies

Other Studies

2 other study(ies) available for obe001 and atosiban

ArticleYear
Oxytocin Receptor Antagonists, Atosiban and Nolasiban, Inhibit Prostaglandin F
    Scientific reports, 2019, 04-08, Volume: 9, Issue:1

    Topics: Adult; Anti-Inflammatory Agents; Calcium; Cells, Cultured; Cyclooxygenase 2; Dinoprost; Female; Humans; MAP Kinase Signaling System; Muscle Contraction; Myometrium; NF-kappa B; Oximes; Oxytocin; Pregnancy; Pyrrolidines; Tocolytic Agents; Vasotocin

2019
Differential Effects of Oxytocin Receptor Antagonists, Atosiban and Nolasiban, on Oxytocin Receptor-Mediated Signaling in Human Amnion and Myometrium.
    Molecular pharmacology, 2017, Volume: 91, Issue:4

    One of the most established roles of oxytocin (OT) is in inducing uterine contractions and labor. Apart from inducing contractions, our recent studies showed that OT can also activate proinflammatory pathways in both human myometrial and amnion cells, which suggests that the proinflammatory role of OT should be taken into account when developing tocolytics targeting the OT/oxytocin receptor (OTR) system. The OTR antagonist, atosiban, is currently used therapeutically for the treatment of preterm labor. We previously showed that atosiban fails to inhibit the proinflammatory effects of OT in human amnion; atosiban alone activates nuclear factor-

    Topics: Amnion; Chemokine CCL5; Enzyme Activation; Female; Humans; Inflammation Mediators; Labor, Obstetric; Mitogen-Activated Protein Kinases; Models, Biological; Myometrium; NF-kappa B; Oximes; Pregnancy; Prostaglandins; Pyrrolidines; Receptors, Oxytocin; Signal Transduction; Up-Regulation; Vasotocin

2017